Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
Contineum Therapeutics Inc Is A Clinical-Stage Biopharmaceutical Company Engaged In The Development Of Oral Small-Molecule Therapies For Neurological, Inflammatory, And Immunological Conditions. The Company Focuses On Developing Selective Compounds Targeting Challenging Molecular Pathways And Has Built A Portfolio Of Small Molecule Drug Candidates. Its Pipeline Includes Drug Candidates In Clinical Development, Such As Pipe-791, An Lpa1 Receptor Antagonist Being Studied For Idiopathic Pulmonary Fibrosis And Chronic Pain, And Pipe-307, An M1 Receptor Inhibitor Being Evaluated For Relapsing-Remitting Multiple Sclerosis And Other Depressive Disorders.